A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This is a medical study that compares two different treatments for people with a type of cancer called multiple myeloma. The study will look at how effective and safe the treatments are, and how they affect the patient's quality of life. The patients in the study have tried other treatments before and will be given either SPd or EloPd.
This is a medical study that compares two different treatments for people with a type of cancer called multiple myeloma. The study will look at how effective and safe the treatments are, and how they affect the patient's quality of life. The patients in the study have tried other treatments before and will be given either SPd or EloPd.
*Third Opinion AI Generated Synopsis
Trial Summary
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: